Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 5/20 | 0.46 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.44 |
| ▸ | IL23R | Q5VWK5 | 6/20 | 0.43 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22807629 | 1.00 | OPRL1 (0.46) | OPRL1KEAP1IL23RCXCR4 | |
| SCHEMBL22807630 | 0.99 | OPRL1 (0.46) | OPRL1KEAP1IL23RCXCR4 | |
| SCHEMBL30005436 | 0.95 | IL23R (0.45) | OPRL1KEAP1IL23RCXCR4 | |
| SCHEMBL29940601 | 0.92 | IL23R (0.46) | IL23RCXCR4 | |
| SCHEMBL31737509 | 0.91 | IL23R (0.45) | OPRL1KEAP1IL23RCXCR4 | |
| SCHEMBL31737829 | 0.91 | CXCR4 (0.44) | OPRL1IL23RCXCR4 | |
| SCHEMBL29524854 | 0.90 | IL23R (0.41) | OPRL1IL23RCXCR4 | |
| SCHEMBL30596889 | 0.90 | IL23R (0.41) | OPRL1IL23RCXCR4 | |
| SCHEMBL23018562 | 0.90 | OPRL1 (0.45) | OPRL1KEAP1IL23R | |
| SCHEMBL29540080 | 0.89 | NPY4R (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3459546-B1 | MULTI-ARM POLYMERIC TARGETING ANTI-CANCER CONJUGATE | BRIGHTGENE BIO MEDICAL TECH CO LTD (CN) | 2022-01-19 | — | — | EP | disclosed |
| US-10869863-B2 | Multi-arm polymeric targeting anti-cancer conjugate | BRIGHTGENE BIO-MEDICAL TECHNOLOGY CO., LTD. (CN) | 2020-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10869863-B2 | Multi-arm polymeric targeting anti-cancer conjugate | TOP2A, TOP1, ABCG2 | OPRL1 3086/4885KEAP1 3561/4885IL23R 314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.